Core Viewpoint - Weigao Blood Purification announced plans to acquire 100% equity of Weigao Purui for approximately 8.511 billion yuan through a share issuance, expanding its business into the development, production, and sales of pre-filled drug delivery systems and automatic safety drug delivery systems [1] Group 1 - The transaction involves purchasing shares from three parties: Weigao Co., Weihai Shengxi, and Weihai Ruiming [1] - The share issuance price is set at 31.29 yuan per share [1] - Upon completion of the transaction, Weigao Purui will become a wholly-owned subsidiary of Weigao Blood Purification [1]

Core Viewpoint - Weigao Blood Products (603014.SH) plans to acquire 100% equity of Weigao Puri through a share issuance for a total consideration of 8.511 billion yuan, with the share price set at 31.29 yuan per share, resulting in approximately 272 million shares being issued, which will account for 39.43% of the total share capital post-issuance [1] Group 1 - The transaction will change the controlling shareholder from Weigao Group to Weigao Shares, while the actual controller remains Chen Xueli, indicating no change in control [1] - The acquisition will expand the company's main business to include pre-filled drug delivery systems and automatic safety drug delivery systems, enhancing its pharmaceutical packaging capabilities [1] Group 2 - Financial projections for the target company indicate revenues of 1.43 billion yuan, 1.67 billion yuan, and 1.41 billion yuan for the years 2023, 2024, and the first nine months of 2025, respectively, with net profits of 483 million yuan, 581 million yuan, and 486 million yuan for the same periods [1] - The assessed value of the target assets shows a 192.90% appreciation based on the income approach as of September 30, 2025 [1] - The transaction counterpart has committed to net profits for Weigao Puri of 640 million yuan, 720 million yuan, and 784 million yuan for the years 2026 to 2028, with adjustments if the transaction is delayed to 2027 [1]

消息面上，1月5日，威高血净（603014）发布公告，拟通过发行股份的方式购买威高股份、威海盛熙和 威海瑞明3名交易对方持有的威高普瑞100%股权，交易价格约为85.11亿元。交易完成后威高普瑞将成 为公司全资子公司，公司主营业务将新增医药包材相关业务。 公告显示，威高普瑞预灌封产品市占率居国内第一。根据中国医药包装协会出具的说明，2022年至2024 年，威高普瑞预灌封产品国内市场占比均超过50%，在国内市场行业中排名第一，在国际市场销量位列 行业前五。威高血净称，本次交易完成后，威高普瑞作为盈利能力较强的优质资产将纳入上市公司合并 报表范围，将进一步提高上市公司盈利能力和投资价值。 威高股份(01066)早盘跌超5%，截至发稿，跌4.91%，报5.04港元，成交额1846.65万港元。 ...

Group 1: Local Government Bonds - Shandong Province issued 723.81 billion yuan in local government bonds, marking the first issuance in the country for the year [2] - The issuance included 467.72 billion yuan in new special bonds and 256.09 billion yuan in refinancing special bonds, focusing on investment in new projects [2] - The Ministry of Finance established a dedicated Debt Management Department to enhance government debt management, which was previously fragmented [2][3] Group 2: Pharmaceutical Industry - In 2025, China approved 76 innovative drugs, significantly surpassing the 48 approved in 2024, with domestic drugs accounting for 85.5% of the total [4] - The total value of authorized transactions for innovative drugs exceeded 130 billion USD, with over 150 transactions, setting a new record [4] - The Chinese pharmaceutical industry has seen substantial growth, particularly in innovative drugs, supported by reforms in drug approval processes and enhanced intellectual property protections [5] Group 3: Automotive Industry - Six major listed car manufacturers reported their 2025 sales, with BYD leading at 4.6024 million units, a 7.73% increase, followed by SAIC and Geely [6] - The growth in sales was driven primarily by the expansion of electric vehicles, with BYD's electric vehicle sales surpassing Tesla for the first time [6][7] - The competitive landscape in the automotive market is intensifying, with companies focusing on optimizing product structures and expanding overseas [7] Group 4: Oil Market - OPEC+ decided to maintain stable oil production levels, postponing planned increases due to ongoing geopolitical tensions [8] - Despite Venezuela's significant oil reserves, production remains low due to insufficient investment, limiting its impact on global supply [8][9] - The global oil market faces challenges in stabilizing prices amid concerns of overproduction and geopolitical factors [9] Group 5: Stock Market Performance - In 2025, 385 Hong Kong stocks saw over 100% growth, with 14 stocks increasing more than tenfold, indicating a strong market performance [14] - The increase in "red stocks" reflects a growing willingness to assign long-term value to internet giants and a high enthusiasm for growth sectors [15] - The A-share market opened positively in 2026, with significant gains across various sectors, particularly in insurance and AI applications [16][17] Group 6: Consumer Products - Prices for certain LABUBU products in the second-hand market have dropped significantly, indicating a shift in supply and demand dynamics [10][11] - The price decline is attributed to increased production by the company, which aims to balance consumer demand with product scarcity [11] Group 7: Technology and AI - Samsung plans to double the number of mobile devices equipped with Google's Gemini AI system, aiming to regain market share in the smartphone sector [12][13] - The integration of AI into various products, including home appliances, highlights a trend towards combining hardware and software solutions [13]

截至1月5日，合富中国总市值92亿元。 同日，海森药业（001367）公告公司部分董事、高级管理人员减持计划实施完成及部分高级管理人员提 前终止减持计划。 去年12月5日，公司董事代亚、副总经理张胜权、副总经理楼岩军、财务总监潘爱娟、董事会秘书胡康 康计划自2025年12月26日至2026年3月25日以集中竞价交易方式合计减持公司股份不超过12.43万股，即 不超过公司总股本的0.0816%。 近日，公司收到财务总监潘爱娟出具的《关于提前终止减持计划的告知函》，基于对公司未来发展前景 的信心和公司价值的合理判断，潘爱娟决定提前终止本次减持计划。截至本公告披露日，潘爱娟女士已 在减持计划期内减持3000股，剩余未减持的2.14万股将不再根据原计划进行减持。另外，董事、高级管 理人员代亚、张胜权、楼岩军、胡康康减持计划已经完成，上述高管合计减持10.29万股，占比 0.0675%。 2026年首个交易日迎来"开门红"，多家百亿以下市值上市公司股东、高管1月5日晚间宣布，提前终止减 持计划。 合富中国（603122）披露，控股股东合富(香港)控股有限公司在2025年12月3日披露了减持计划，拟通 过大宗交易方式和集 ...

Core Viewpoint - Weigao Blood Purification (603014.SH) plans to issue shares to acquire 100% equity of Weigao Purui held by Weigao Co., Weihai Shengxi, and Weihai Ruiming for a transaction price of 8.511 billion yuan [1] Group 1: Transaction Details - The transaction price, excluding the amount for supporting fundraising, is set at 8.511 billion yuan [1] - The acquisition will add new business lines in pre-filled drug delivery systems and automatic safety drug delivery systems, enhancing the company's product offerings [1] Group 2: Strategic Benefits - Post-transaction, the company aims to integrate the target company's technological expertise and product layout to expand into the pharmaceutical packaging sector [1] - The collaboration is expected to leverage the company's hollow fiber filtration technology and the target company's extensive customer resources in biopharmaceuticals, enabling mutual empowerment in the biopharmaceutical filter business [1]

威高血净（603014）(603014.SH)发布公告，公司拟发行股份购买威高股份、威海盛熙和威海瑞明持有 的威高普瑞100%股权，交易价格(不含募集配套资金金额)为85.11亿元。 本次交易后，公司主营业务将新增预灌封给药系统及自动安全给药系统等医药包材的研发、生产与销 售。本次交易完成后，公司可以通过整合标的公司技术积累和产品布局，将产品线扩展到医药包材领 域。同时，本次交易完成后，通过充分协同公司自身中空纤维过滤技术优势与标的公司在生物制药领域 的丰富客户资源，可以实现双方在生物制药滤器业务上技术储备与客户资源的双向赋能，共同开拓以生 物制药滤器为重点的生物制药上游业务市场。 ...

Core Viewpoint - The company, Opcon Vision (300595), has recently received a Drug Production License for eye drops from the Anhui Provincial Drug Administration, marking its first acquisition of such a license [1] Group 1: License Acquisition - The Drug Production License is a significant regulatory milestone for the company, allowing it to proceed with further necessary regulatory steps for commercialization [1] - The company must still complete product registration applications, on-site inspections, and compliance checks with Good Manufacturing Practices (GMP) before obtaining the Drug Registration Certificate [1] Group 2: Impact on Business - The acquisition of the Drug Production License is not expected to have a significant short-term impact on the company's operating performance [1]

Group 1 - Postal Savings Bank announced a cash dividend distribution of 14.772 billion yuan for the first half of 2025, with a dividend of 1.23 yuan per 10 shares [1] - Xinke Mobile plans to reduce its shareholding by up to 1%, amounting to a maximum of 34.1875 million shares, due to funding needs [1] - Defu Technology signed a cooperation letter with a leading domestic CCL company to supply high-end electronic circuit copper foil products, which is expected to positively impact the company's performance in 2026 [1] Group 2 - Sanxia New Materials intends to acquire 40% equity of Lingang New Materials for a transaction amount of 0 yuan, which constitutes a related party transaction [2] - Fulim Precision plans to invest a total of 87 billion yuan in projects for the production of high-end lithium iron phosphate for energy storage, with the main project estimated at 60 billion yuan [3] - Heng Rui Pharmaceutical received approval for clinical trials of HRS9531 injection in combination with HRS-5817 injection for treating obesity in adults [3] Group 3 - Quartz Co. was fined 2.7 million yuan for commercial secret infringement, with the company being the victim in this case [5] - ST Renfu received approval for clinical trials of HW221043 tablets for late-stage solid tumors, with no similar drugs approved domestically or internationally [6] - Tianchen Medical signed a strategic cooperation agreement with Inspur Digital Technology to promote innovation in medical robotics and smart manufacturing [6] Group 4 - Xusheng Group received a notification from a North American electric vehicle manufacturer for a project with an estimated total sales amount of approximately 7.8 billion yuan over its lifecycle [6] - Deyun Co. announced that its actual controller was arrested for illegal public deposit collection, but this does not significantly impact the company's operations [7] - Shengyang Technology's subsidiary is advancing a project with a global satellite operator in South America, focusing on software licensing and product delivery [7] Group 5 - Hefei China announced a 1% reduction in shares by its controlling shareholder, who terminated the reduction plan early to express confidence in the company's future [8] - Weigao Blood Purification plans to acquire 100% equity of Weigao Purui for 8.511 billion yuan, which will expand its business into drug delivery systems [10]

威高血净公告称，威高股份及其一致行动人拟通过发行股份的方式，购买威高普瑞100%的股权。本次 收购完成后，威高股份及其一致行动人将合计持有威高血净84.36%的股份，不会影响上市公司的上市 地位。标的公司股权全部权益的评估值为85.11亿元。本次交易后，上市公司主营业务将新增预灌封给 药系统及自动安全给药系统等医药包材的研发、生产与销售。 ...